行情

ALNY

ALNY

阿里拉姆制药
NASDAQ

实时行情|Nasdaq Last Sale

123.76
-0.47
-0.38%
盘后: 123.80 +0.04 +0.03% 17:52 12/06 EST
开盘
124.34
昨收
124.23
最高
125.72
最低
123.17
成交量
88.89万
成交额
--
52周最高
125.72
52周最低
60.27
市值
137.78亿
市盈率(TTM)
-15.9528
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALNY 新闻

  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.2天前
  • Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow
  • Seeking Alpha - Article.3天前
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.3天前
  • Alnylam Continues To Deliver On RNAi Pipeline With Alternative Treatment Option For Rare Disease
  • Seeking Alpha - Article.4天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

ALNY 简况

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
展开

Webull提供Alnylam Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。